The metabolism of Paricalcitol can be decreased when combined with Lovastatin. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. The metabolism of Paricalcitol can be increased when combined with Rifampicin. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Clemastine. Paricalcitol may increase the arrhythmogenic activities of Ouabain. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The metabolism of Paricalcitol can be increased when combined with Primidone. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. Danazol may increase the hypercalcemic activities of Paricalcitol. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. Indapamide may increase the hypercalcemic activities of Paricalcitol.